INTRODUCTION
Malondialdehyde (MDA) is a highly reactive endogenous product of thromboxane synthesis in the prostagland and lipid peroxidation by reactive oxygen species [1, 2] . Peroxidation of polyunsaturated fatty acids by ROS is the major cause of the formation of toxic and highly reactive aldehydes such as N-()- (2-propenal) , MDA and 4-hydroxy-nonenal (HNE) in vivo [3] . The toxicity of MDA arises from its high reactivity, particularly towards proteins and DNA [4] [5] [6] . T lymphocytes are critical regulators of the inflammatory response. They can be classified into subsets based on the signature cytokines they secrete and the transcription factors they express. One lineage of the T lymphocytes is the T helper (Th) cells, which were implicated in the pathogenesis of a variety of inflammatory diseases. Th1 cells secrete IFN-γ and Th2 cells secrete IL-4 [7] . Th17 cells are the most recently identified highly pro-inflammatory subset of Th cells. They are characterized by the secretion of their signature cytokine IL-17 [7] [8] [9] . IL-17 family cytokines have recently gained attention due to their involvement in autoimmune and inflammatory diseases. Based on the sequence homology with IL-17A, five other interleukins have been identified: IL-17B, IL-17C, IL-17D, IL-17E (also known as IL-25) and IL-17F. IL-17F has the highest sequence identity with IL-17A and IL-17E has the lowest [10] . The divergence of IL-17E from IL-17A also reflects in its biological functions. IL-17A and IL-17F induce the expression of pro-inflammatory cytokines like IL-6, IL-8, TNF-and IL-1and enhance neutrophil migration [11] [12] [13] , while IL-17E promotes eosinophil infiltration and the expression of Th2 cytokines like IL-4, IL-5 and IL-13 [14] . This cytokine has drawn particular attention due its ability to play a dual role under inflammatory conditions [15] . Recent studies have shed light on the pathogenic role of IL-17E in asthma, airway inflammatory disease and allergic lung disease [16] [17] [18] and its protective role in animal models of diabetes, ulcerative colitis and experimental autoimmune encephalomyelitis [19] [20] [21] [22] [23] . There have been recent reports of mature B and plasma cells expressing IL-17E in the intima and adventitia of advanced atherosclerotic plaques and extensive expression of IL-17E in atherosclerotic arteries [24, 25] . Elevated plasma concentrations of MDA were seen in diabetes, and anti-MDA adduct antibody studies demonstrated significant levels of MDA in atherosclerotic lesions and diabetic kidneys [25] [26] [27] [28] [29] . We recently reported that treating lymphocytes with MDA led to changes in the inflammatory cytokine/chemokine milieu [30] . We investigated the pro-inflammatory effects of MDA in lymphocytes through cytokine array studies and reported that IL-17E is a candidate gene induced by MDA in lymphocytes. We also reported increased IL-17E mRNA expression in lymphocytes from diabetes patients [30, 31] . In this study, we describe the molecular mechanisms by which MDA regulates IL-17E expression in lymphocytes and also demonstrate that MDA induces skewing to Th17 polarization.
MATERIALS AND METHODS

Materials
RPMI-1640 media, penicillin-streptomycin, HEPES and fetal bovine serum (FBS) were purchased from Gibco-Invitrogen. Restriction enzymes and T4 DNA ligase were from New England Biolabs. The Nucleofector transfection kit was from Lonza. Actinomycin-D and N-acetyl cysteine (NAC) were from Sigma. BAY11-7082, SB-202190, Bisindolylmaleimide (GFX) and PD-98059 were from Calbiochem. The Human IL-17E ELISA kit was from Peprotech. The RNeasy real-time PCR primers and Plasmid MiniPrep kits were from Qiagen. RT-PCR reagents were from Thermo-Abgene. 18S primer and Power SYBR green real-time master mix was from Ambion. The human Th1, Th2 and Th17 immunophenotyping kit was from BD Biosciences. HiSep LSM was from HiMedia. The luciferase assay system was from Promega.
Cell culture and treatments
The Jurkat T-cell line was obtained from the NCCS (National Centre for Cell Science, Pune) and cultured in endotoxin free RPMI-1640 medium with 5.5 mmol/l D(+) normal glucose (NG) in a 5% CO 2 incubator at 37ºC. 
Isolation of human peripheral blood lymphocytes (PBLCs)
Blood (50 ml) was collected from adult donors in the presence of an anticoagulant in accordance with a University Ethical Committee protocol (approval number DM/2009/101/04 from the Institutional Ethics committee for Human Research, Bharathidasan University). There were 9 healthy volunteers and 9 subjects with clinically established diabetes (4 with type 1 and 5 with type 2).
All provided written informed consent. Diabetes patients with poor glycemic control were selected for this study (HbA 1C range 7.1 to 8.2). The time since diagnosis ranged from 2 to 30 years. All of the patients were on insulin and hypoglycemic drugs, but none were on anti-inflammatory or anti-oxidant medications. Peripheral blood lymphocytes were isolated as described previously [30, 31] . Approximately 1 x 10 6 cells were treated with MDA for 16 h.
RNA preparation and PCR
Total RNA extraction, reverse transcription and real-time PCR were used to measure mRNA expression using gene-specific primers. 18S rRNA and GAPDH were used as the internal controls, as described previously [30, 31] .
Measurement of secreted IL-17E protein levels
The IL-17E protein level was assayed in conditioned media from Jurkat T-cells (5 x 10 5 cells/ml) cultured in RPMI 1640 medium containing 2% FBS treated with or without MDA using a sandwich ELISA kit as per the manufacturer's instructions. The medium alone, without cells, was incubated under the same conditions for use as a blank control. In addition, normal and diabetes patient serum samples were analyzed for the IL-17E protein level.
Plasmid construction, DNA transfection and luciferase assay Construction of the specific regions for the human IL-17E (-1535/+109) promoters in the luciferase reporter vector pGL3 basic vector was accomplished via PCR using human genomic DNA primers. For IL-17E, the forward primer was 5'TCCATGTCATGGTACCATTGTCGGA3' and the reverse primer was 5'CGTGGAAGCTTGCTGACTGGAGCAGGTT3'. The upstream PCR primer contained a KpnI recognition site (underlined), and the downstream primer contained a HindIII recognition site (underlined), which forced cloning of the fragments in the desired orientation into the pGL3 basic vector. The orientation and sequence of all of the constructs were verified by direct sequencing using an Applied Biosystems XL-3730 DNA sequencer and the sequence was submitted to GenBank (NCBI Accession No. KC189003). Transfection and luciferase assays were performed as described previously. Jurkat T-cells were transfected with 0.5 g of plasmids using Nucleofector kits and cultured for a further 16 h in NG or MDA. The luciferase activity assays were performed as per the manufacturer's protocol.
Immunophenotyping analysis of Th1, Th2 and Th17
Functionally-polarized T-cell subsets were immunophenotyped via flow cytometry based on their distinctive patterns of cytokine secretion using a human Th1, Th2 and Th17 phenotyping kit. Briefly, about 1 x 10 6 PBLCs isolated from the healthy donors using HiSep as described above were suspended in cold BD Cytofix fixation buffer and permeabilized with BD perm buffer. The permeabilized cells were stained with a four-color cocktail of fluorescent antibodies that are specific for human anti-CD4+-PERCP-CY5.5 antibody, anti-IFN-γ-FITC antibody (for Th1), anti-IL-4-APC antibody (for Th2) and anti-IL-17A-PE antibody (for Th17). Data acquired on a BD FACS Aria (BD Biosciences) were analyzed with FACSdiva software. Lymphocytes were gated using an FSC and SSC bivariate plot and CD4+ and Th1, Th2 and Th17 populations were calculated via quadrant dot plot analysis and univariate histograms.
Data analyses
Data from multiple experiments were expressed as means ± SEM. Paired Student's t-tests were used to compare pairs and ANOVA was used for multiple comparisons. All of the statistical analyses were done using PRISM software (GraphPad Prism V5.0). A p value < 0.05 was considered statistically significant.
RESULTS
MDA induces the expression of IL-17A and IL-17E, but not IL-17B, IL-17C, IL-17D or IL-17F in Jurkat T-cells
In our previous study, we reported that MDA can induce the mRNA expression of IL-17A and IL-17E in Jurkat T-cells. In this study, we first examined the progress of MDA-mediated regulation mRNA expression of the IL-17 family of cytokines by treating Jurkat T-cells with 50 M MDA for 4, 8, 16 and 24 h and analyzing the mRNA expression of these cytokines via reverse transcriptase PCR. The results (Fig. 1A-F) suggest that MDA significantly induced the expression of IL-17A and IL-17E in a time-dependent manner. The expression of IL-17A gradually increased and reached its peak at 24 h (p < 0.05), whereas IL-17E attained its optimal mRNA expression at 16 h (p < 0.01) and then decreased.
Characterization of MDA-induced IL-17E expression via PCR and ELISA
Next, to check the dose-response effect of MDA on IL-17E expression, we treated Jurkat T-cells with different concentrations of MDA (10, 25, 50, 75 and 100M) for 16 h and analyzed IL-17E mRNA expression via PCR. MDA induced the expression of IL-17E in a dose-dependent manner ( Fig. 2A) . The maximal increase in mRNA expression was observed at 75 M concentrations of MDA. For the rest of the experiments we selected a treatment time of 16 h and a dose of 75M as optimal conditions. Next, we analyzed the MDA-induced IL-17E mRNA expression via PCR (Fig. 2B ) and found a 2-to 3-fold (p < 0.05) increase in IL-17E mRNA expression in MDA-treated Jurkat T-cells. We also analyzed MDA-induced IL-17E protein expression via sandwich ELISA using cell culture supernatants from Jurkat T-cells. The results in Fig. 2C show a significant (2-fold; p < 0.05) increase in IL-17E protein expression induced by MDA in Jurkat T-cells. MDA induces IL-17E mRNA expression in peripheral blood lymphocytes and IL-17E protein levels are increased in diabetes patient serum We checked whether MDA can induce IL-17E mRNA expression in PBLCs. Even though Jurkat T-cells represent typical lymphocytes, their phenotype may not be identical with that of actual PBLCs. We isolated PBLCs from healthy volunteers and treated them with or without MDA for 16 h and analyzed the IL-17E mRNA expression via PCR. A significant (2-fold; p < 0.05) induction in IL-17E mRNA expression by MDA was found (Fig. 3A) . Next, we checked IL-17E protein levels in diabetes patients with elevated serum MDA levels to establish the in vivo relevance to our in vitro results. In our previous study, we reported elevated IL-17E mRNA expression in diabetes patients. Therefore, we checked the IL-17E protein levels in serum from diabetic volunteers via ELISA. A significant (2-fold; p < 0.01) increase in IL-17E protein levels in diabetic volunteers compared with control healthy volunteers was found (Fig. 3B) . 
control). C -Conditioned medium supernatants of
Jurkat T-cells treated with or without MDA were assayed for IL-17E protein levels via ELISA using a specific human IL-17E antibody. Results shown are means ± SEM from three experiments run in triplicate. Fig. 3 . Analyses of MDA-induced IL-17E mRNA expression via RT-PCR in human PBLC and IL-17E protein levels in diabetes patient serum. A -MDA induces in IL-17E mRNA expression in PBLCs from normal volunteers. PBLCs were isolated from normal healthy non-diabetic adult donors and were stimulated with MDA (75 M) for 16 h. IL-17E mRNA levels were measured via RT-PCR analysis as described in Fig. 1 (*p < 0 .05, **p < 0.01 vs. control). B -Serum from control and diabetic subjects was assayed for IL-17E protein via ELISA (*p < 0.05, **p < 0.01 vs. control subjects).
MDA induces IL-17E mRNA expression via promoter activation
We assessed whether MDA-induced IL-17E mRNA expression is due to increased transcription. For this, we pre-treated Jurkat T-cells with Act-D, a transcription inhibitor, for 1 h and treated Jurkat T-cells with MDA for 16 h.
The results (Fig. 4A) revealed that MDA-induced IL-17E expression was significantly blocked upon pre-treatment with Act-D. This indicates that MDA-induced IL-17E expression is due to increased transcription. To further examine whether MDA can stimulate IL-17E promoter activation, we used the luciferase reporter gene assay. We cloned a human IL-17E (phIL-17E-Luc- ( (Fig. 5A-F) show that MDA-induced IL-17E mRNA expression was significantly blocked by inhibitors of the NAC, NF-B, p38 MAPK, PKC and ERK pathways in a dose-dependent manner with the highest inhibition observed at the highest concentrations. 
MDA treatment skews T-lymphocyte into the Th17 subset
To identify the effect of MDA on Th1, Th2 and Th17 polarization into a particular subset of lymphocytes, we quantified the levels of the Th1, Th2 and Th17 populations using flow cytometry. PBLCs were treated either with or without MDA for various time intervals (4-72 h) and labeled with their signature cytokines, like IL-4, IFN- and IL-17. The results (Fig. 6A-B) revealed that PBLCs treated with MDA for 72 h showed a significant (2-fold) increase in the level of IL-17A-positive CD4+ cells compared to the control cells (Fig. 6C) . However, IL-4 and IFN-positive CD4+ cells showed no significant change upon MDA treatment. These results suggest that MDA can skew the T-cell population into the highly pathogenic Th17 subset. 
DISCUSSION
Oxidative stress-induced lipid peroxidation results in the formation of diversified aldehydes, such as MDA and HNE, which are highly reactive. They are considered to be secondary toxic messengers that augment initial free radical events and signaling mediators involved in cell signal transduction and the regulation of gene expression [30, 32] . Mounting evidence shows that the tissue and blood levels of MDA are higher in a number of human diseases, including inflammation, diabetes, atherosclerosis, neurodegenerative diseases and cancer [33, 35] . In our previous study, we demonstrated the pro-inflammatory effects of MDA in lymphocytes. MDA was found to induce the expression of IL-17E, a distinct member of the IL-17 family of cytokines. Here, we report for the first time that the ALE precursor MDA can induce the expression of IL-17E through transcriptional activation. This cytokine has been described as a double-edged sword in the control of inflammatory and immune responses [15] . We characterized MDA-induced IL-17E expression using PCR and ELISA and found that MDA can induce the expression of IL-17E in a time-and dosedependent manner in Jurkat T-cells. In addition, IL-17E upregulation was also seen in PBLCs treated with MDA under similar conditions. It was also observed that in diabetes patients with elevated MDA levels, the IL-17E protein level significantly increased, which correlates well with our previous report. Further pre-treatment with the transcription inhibitor actinomycin-D effectively blocks MDA-induced IL-17E expression, suggesting the involvement of transcriptional regulation. Next, with the aid of the luciferase reporter gene assay, we studied MDAinduced IL-17E promoter activation and found that MDA is capable of stimulating IL-17E promoter activation. One of the key transcriptional element binding sites present in the IL-17E promoter is NF-B. Many lines of evidence described NF-B as an oxidative stress sensitive transcription factor that can activate the transcription of several candidate genes [36] [37] [38] . Earlier, we also demonstrated that MDA can induce oxidative stress in lymphocytes [30] . Therefore, we decided to check whether NF-B activation is involved in MDAinduced IL-17E expression. Studies with pharmacological inhibitors of NF-B and antioxidant NAC suggested a role for both these mechanisms in MDA-induced IL-17E expression. In addition, studies with kinase inhibitors revealed the involvement of upstream signaling cascades like PKC, ERK and p38MAPK in MDA-induced IL-17E expression in Jurkat T-cells. After exploring the molecular mechanisms of MDA-induced IL-17E expression, we decided to examine the effect of prolonged MDA exposure on T-cell differentiation. Polarization of naïve T cells to a particular subset is tightly regulated by the local cytokine environment, co-stimulatory signals and lineagespecific transcription factors that either activate or attenuate specific T-cell lineage programs [39] . IL-12 is the initiator for Th1 polarization, which activates STAT-4, resulting in sequential induction of T-bet, the master regulator of Th1 lineage differentiation. On the other hand, IL-4, the initiator of Th2 polarization, activates STAT-6, which in turn triggers GATA-3 induction, resulting in the Th2 lineage [38, 40] . Various study groups have demonstrated that Th17 polarization is driven by IL-6, IL-21 and TGF-. Initially IL-6 induces the expression of IL-21 through STAT-3 activation. Later, IL-6 and IL-21 together with TGF- suppress FOXP3 expression, inducing Th17 differentiation [40] [41] [42] [43] . The biological roles of IL-17E were studied through both exogenous administration and transgenic overexpression of IL-17E in mice. Salient features of IL-17E-mediated immune responses include eosinophilic infiltration and the expression of Th2 cytokines like IL-4, IL-5 and IL-13 [13, 44] . The functional receptor for IL-17E is IL-17RB, which is also known as IL-17 receptor homolog (IL-17Rh). However, experiments with IL-17ra-/-and IL-17rb-/-mice revealed that both IL-17RA and IL-17RB are required for effective IL-17E signaling [45] [46] [47] [48] [49] [50] . In our previous report, we found 3-fold upregulation of IL-17RB expression together with IL-17E upregulation upon MDA treatment. Thus, an effective amplification of IL-17E signaling is plausible in T cells under elevated MDA conditions, which could elicit a Th2 immune response. However, in our time course analysis, we noted that IL-17A expression increased gradually up to 24 h, whereas IL-17E expression started declining after 16 h. Immunophenotyping analyses after 72 h of MDA treatment showed a significantly increased Th17 population rather than an increased Th2 population, suggesting the recruitment of other Th17 polarizing factors during the later phase of MDA treatment rather than in the acute phase. Further studies are needed to elaborate on the immunomodulatory effects of MDA on lymphocyte lineage switching and the molecular mechanisms finetuning the T-helper cell polarization. We conclude that ALE precursor MDA can transcriptionally regulate the expression of IL-17E in lymphocytes and induce the Th17 response after chronic exposure.
